drugset
drugset / Trial / NCT02824666

Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242

NCT02824666 ↗

Phase 1 Completed 7 enrolled Braeburn Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study involves evaluating the occupancy of ATI-9242 at steady state at three different dose levels on D2 receptors in the brain using \[18F\] Fallypride PET in up to three cohorts of subjects.

Timeline

Start
2016-06-20
Primary completion
2016-09-06
Completion
2016-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ATI-9242 Unknown 0.5 mg/kg Intravenous
Subject ATI-9242 Unknown 1 mg/kg Intravenous
Subject ATI-9242 Unknown 2 mg/kg Intravenous

Indications

schizophrenia